PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
No Data
No Data available this quarter, please select a different quarter.
4.38
Similar net debt to CRVO's 4.24. Guy Spier would examine if industry leverage norms make sense for both companies.
No Data
No Data available this quarter, please select a different quarter.
4.19
Current ratio below 50% of CRVO's 19.92. Jim Chanos would check for potential working capital crisis.
No Data
No Data available this quarter, please select a different quarter.